Luteinizing Hormone-Releasing Hormone (LHRH) Conjugated Magnetite Nanoparticles as MRI Contrast Agents for Breast Cancer Imaging
Targeted magnetic resonance imaging (MRI) contrast agents offer platforms for the specific detection of many diseases, including cancer. This study explores the applicability of luteinizing hormone-releasing hormone-conjugated PEG-coated magnetite nanoparticles (LHRH-MNPs) to the enhancement of trip...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-07-01
|
| Series: | Applied Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3417/10/15/5175 |
| _version_ | 1797561143706779648 |
|---|---|
| author | Jingjie Hu John Obayemi Karen Malatesta Edward Yurkow Derek Adler Winston Soboyejo |
| author_facet | Jingjie Hu John Obayemi Karen Malatesta Edward Yurkow Derek Adler Winston Soboyejo |
| author_sort | Jingjie Hu |
| collection | DOAJ |
| description | Targeted magnetic resonance imaging (MRI) contrast agents offer platforms for the specific detection of many diseases, including cancer. This study explores the applicability of luteinizing hormone-releasing hormone-conjugated PEG-coated magnetite nanoparticles (LHRH-MNPs) to the enhancement of triple negative breast cancer (TNBC) detection. In vitro MRI studies were first performed, showing the consistent darkening effect of both MNPs and LHRH-MNPs in T2-weighted maps. Using a mouse model with an induced subcutaneous tumor, MNPs and LHRH-MNPs were injected into xenograft MDA-MB-231. This was done through intratumoral and intravenous injections, respectively, enabling direction comparisons of the two nanoparticles. Intratumorally injected LHRH-MNPs maintained T2 signals within the breast tumors up to two weeks, revealing long-term tumor enhancement ability, while the signal started to recover towards the contrast of the original tumor before injection in the case of MNPs at 24 h post injection. For intravenous administration, LHRH-MNPs continued to darken breast tumor 24 h following injection, whereas contrast enhancement was not obvious in animals injected with MNPs. These results show the potential of LHRH-MNPs as negative contrast agents for the specific detection of TNBC. |
| first_indexed | 2024-03-10T18:10:04Z |
| format | Article |
| id | doaj.art-676f4786cbf1446e85ec0298c0212316 |
| institution | Directory Open Access Journal |
| issn | 2076-3417 |
| language | English |
| last_indexed | 2024-03-10T18:10:04Z |
| publishDate | 2020-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Applied Sciences |
| spelling | doaj.art-676f4786cbf1446e85ec0298c02123162023-11-20T08:10:09ZengMDPI AGApplied Sciences2076-34172020-07-011015517510.3390/app10155175Luteinizing Hormone-Releasing Hormone (LHRH) Conjugated Magnetite Nanoparticles as MRI Contrast Agents for Breast Cancer ImagingJingjie Hu0John Obayemi1Karen Malatesta2Edward Yurkow3Derek Adler4Winston Soboyejo5Department of Mechanical and Aerospace Engineering, Princeton University, Olden Street, Princeton, NJ 08544, USADepartment of Mechanical and Aerospace Engineering, Princeton University, Olden Street, Princeton, NJ 08544, USADepartment of Mechanical and Aerospace Engineering, Princeton University, Olden Street, Princeton, NJ 08544, USAMolecular Imaging Center, Rutgers University, 41 Gordon Road, Piscataway, NJ 08854, USAMolecular Imaging Center, Rutgers University, 41 Gordon Road, Piscataway, NJ 08854, USADepartment of Mechanical and Aerospace Engineering, Princeton University, Olden Street, Princeton, NJ 08544, USATargeted magnetic resonance imaging (MRI) contrast agents offer platforms for the specific detection of many diseases, including cancer. This study explores the applicability of luteinizing hormone-releasing hormone-conjugated PEG-coated magnetite nanoparticles (LHRH-MNPs) to the enhancement of triple negative breast cancer (TNBC) detection. In vitro MRI studies were first performed, showing the consistent darkening effect of both MNPs and LHRH-MNPs in T2-weighted maps. Using a mouse model with an induced subcutaneous tumor, MNPs and LHRH-MNPs were injected into xenograft MDA-MB-231. This was done through intratumoral and intravenous injections, respectively, enabling direction comparisons of the two nanoparticles. Intratumorally injected LHRH-MNPs maintained T2 signals within the breast tumors up to two weeks, revealing long-term tumor enhancement ability, while the signal started to recover towards the contrast of the original tumor before injection in the case of MNPs at 24 h post injection. For intravenous administration, LHRH-MNPs continued to darken breast tumor 24 h following injection, whereas contrast enhancement was not obvious in animals injected with MNPs. These results show the potential of LHRH-MNPs as negative contrast agents for the specific detection of TNBC.https://www.mdpi.com/2076-3417/10/15/5175triple negative breast cancer (TNBC)luteinizing hormone-releasing hormone (LHRH)magnetite nanoparticlesmagnetic resonance imaging (MRI)cancer detection |
| spellingShingle | Jingjie Hu John Obayemi Karen Malatesta Edward Yurkow Derek Adler Winston Soboyejo Luteinizing Hormone-Releasing Hormone (LHRH) Conjugated Magnetite Nanoparticles as MRI Contrast Agents for Breast Cancer Imaging Applied Sciences triple negative breast cancer (TNBC) luteinizing hormone-releasing hormone (LHRH) magnetite nanoparticles magnetic resonance imaging (MRI) cancer detection |
| title | Luteinizing Hormone-Releasing Hormone (LHRH) Conjugated Magnetite Nanoparticles as MRI Contrast Agents for Breast Cancer Imaging |
| title_full | Luteinizing Hormone-Releasing Hormone (LHRH) Conjugated Magnetite Nanoparticles as MRI Contrast Agents for Breast Cancer Imaging |
| title_fullStr | Luteinizing Hormone-Releasing Hormone (LHRH) Conjugated Magnetite Nanoparticles as MRI Contrast Agents for Breast Cancer Imaging |
| title_full_unstemmed | Luteinizing Hormone-Releasing Hormone (LHRH) Conjugated Magnetite Nanoparticles as MRI Contrast Agents for Breast Cancer Imaging |
| title_short | Luteinizing Hormone-Releasing Hormone (LHRH) Conjugated Magnetite Nanoparticles as MRI Contrast Agents for Breast Cancer Imaging |
| title_sort | luteinizing hormone releasing hormone lhrh conjugated magnetite nanoparticles as mri contrast agents for breast cancer imaging |
| topic | triple negative breast cancer (TNBC) luteinizing hormone-releasing hormone (LHRH) magnetite nanoparticles magnetic resonance imaging (MRI) cancer detection |
| url | https://www.mdpi.com/2076-3417/10/15/5175 |
| work_keys_str_mv | AT jingjiehu luteinizinghormonereleasinghormonelhrhconjugatedmagnetitenanoparticlesasmricontrastagentsforbreastcancerimaging AT johnobayemi luteinizinghormonereleasinghormonelhrhconjugatedmagnetitenanoparticlesasmricontrastagentsforbreastcancerimaging AT karenmalatesta luteinizinghormonereleasinghormonelhrhconjugatedmagnetitenanoparticlesasmricontrastagentsforbreastcancerimaging AT edwardyurkow luteinizinghormonereleasinghormonelhrhconjugatedmagnetitenanoparticlesasmricontrastagentsforbreastcancerimaging AT derekadler luteinizinghormonereleasinghormonelhrhconjugatedmagnetitenanoparticlesasmricontrastagentsforbreastcancerimaging AT winstonsoboyejo luteinizinghormonereleasinghormonelhrhconjugatedmagnetitenanoparticlesasmricontrastagentsforbreastcancerimaging |